Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 8,334,882 | $149,694,481 | +1% | 2.25% |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 5,650,000 | $101,474,000 | 6.04% | |
| 3. | Saturn V Capital Management Xiaoying Tian | 4,624,101 | $83,048,854 | +7% | 11.91% |
| 4. | Driehaus Capital Richard Driehaus | 3,036,970 | $54,543,981 | +2% | 0.32% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,900,000 | $34,124,000 | -47% | 0.05% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.51 | 3,800 | $51,338.00 | 66,900 | 2026-05-21 | Filing | |
| $12.45 | 8,100 | $100,845.00 | 63,100 | 2025-12-23 | Filing | |
| $3.70 | 10,000 | $37,005.00 | 10,000 | 2025-03-20 | Filing | |
| $2.53 | 40,000 | $101,368.00 | 233,464 | 2024-09-12 | Filing | |
| $2.13 | 50,000 | $106,590.00 | 55,000 | 2024-09-05 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.61 | 15,000 | $264,121.50 | 179,090 | 2026-07-10 | Filing | |
| $18.32 | 15,000 | $274,746.00 | 194,090 | 2026-07-09 | Filing | |
| $14.47 | 29,282 | $423,760.32 | 3,334,616 | 2026-03-02 | Filing | |
| $14.48 | 29,282 | $424,120.49 | 3,334,683 | 2026-03-02 | Filing | |
| $14.58 | 6,461 | $94,205.26 | 169,295 | 2026-03-02 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,727,909 | $300,433,246 | 0.01% | |
| 2. | 8,827,085 | $158,534,442 | 0% | |
| 3. | 6,243,812 | $112,138,864 | 2.7% | |
| 4. | 5,236,102 | $94,014,211 | 0.04% | |
| 5. | 4,224,224 | $75,867,063 | 0% |